Danazol therapy for idiopathic thrombocytopenic purpura (ITP)

G. Nalli, M. R. Sajeva, G. Carnevale Maffe, E. Ascari

Research output: Contribution to journalArticle

Abstract

Fourteen patients with idiopathic thrombocytopenic purpura (ITP) refractory to steroids and/or splenectomy were treated with Danazol (200 mg 3 times a day), an androgen with reduced virilizing capacity. After a two-month trial with this drug 5 patients experienced a sustained increase in platelet count. In 3 cases remission lasted more than 12 months and in 2 others it was transient. The drug was well-tolerated in all cases; one patient showed worsening of bleeding due to activation of fibrinolysis.

Original languageEnglish
Pages (from-to)55-57
Number of pages3
JournalHaematologica
Volume73
Issue number1
Publication statusPublished - 1988

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Nalli, G., Sajeva, M. R., Carnevale Maffe, G., & Ascari, E. (1988). Danazol therapy for idiopathic thrombocytopenic purpura (ITP). Haematologica, 73(1), 55-57.